عنوان
پدید آورنده
موضوع
رده
QP551 .A3257 2019
QP551
.
A3257
2019
کتابخانه
محل استقرار
INTERNATIONAL STANDARD BOOK NUMBER
(Number (ISBN
1788015711
(Number (ISBN
1788017323
(Number (ISBN
9781788015714
(Number (ISBN
9781788017329
Erroneous ISBN
1788012097
Erroneous ISBN
9781788012096
TITLE AND STATEMENT OF RESPONSIBILITY
Title Proper
Advances in nucleic acid therapeutics /
General Material Designation
[Book]
First Statement of Responsibility
edited by Sudhir Agrawal and Michael J. Gait.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Cambridge, UK :
Name of Publisher, Distributor, etc.
Royal Society of Chemistry,
Date of Publication, Distribution, etc.
[2019]
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
1 online resource (1 volume)
SERIES
Series Title
Drug discovery series ;
Volume Designation
no. 68,
ISSN of Series
2041-3203
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references and index.
CONTENTS NOTE
Text of Note
Intro; Half Title; Series Editors; Title; Copyright; Foreword; Preface; Contents; Chapter 1 History and Development of Nucleotide Analogues in Nucleic Acids Drugs 1; 1.1 Introduction; 1.2 The Antisense Concept; 1.3 Developments in Oligonucleotide Synthesis; 1.4 Choices for Antisense Oligodeoxynucleotide Modifications; 1.4.1 Backbone Modifications; 1.4.2 Heterocyclic Bases; 1.4.3 Sugar Modifications; 1.5 Gapmers Using Combinations of Modified Oligodeoxy and/or Oligoribonucleotides; 1.6 Antisense Conjugates; 1.7 The Role of Innate Immune Receptors in Nucleic Acid Therapeutics
Text of Note
1.8 Future DirectionsAcknowledgements; References; Chapter 2 Mechanisms of Antisense Oligonucleotides 22; 2.1 Introduction; 2.2 RNase H and ASO Action; 2.3 ASOs and Regulation of Splicing; 2.4 ASOs and Activation of Frataxin, a Case Study for an Emerging Mechanism; 2.5 Summary; Acknowledgements; References; Chapter 3 The Medicinal Chemistry of RNase H-activating Antisense Oligonucleotides 32; 3.1 Introduction to Gapmers; 3.2 Human RNase H1; 3.2.1 Biochemistry of Human RNase H1; 3.2.2 Structural Biology of Human RNase H1; 3.3 Structure-Activity Relationships of Gap Modifications
Text of Note
3.5.4 ASO Gapmer Duplexes3.6 Control of Protein Binding; 3.6.1 Interaction of Gapmer ASOs with Plasma Proteins; 3.6.2 Interaction of Gapmer-ASOs with Cell-surface Proteins; 3.6.3 Targeting Cell-surface Proteins for Cell-specific Delivery of Gapmers; 3.6.4 Avoiding Interactions with TLR Receptors to Avoid Immune-stimulatory Toxicities; 3.6.5 Optimizing Intracellular Distribution; 3.7 Conclusions; References; Chapter 4 Antisense Technology: Liver Targeting and Beyond for Drug Discovery 62; 4.1 Introduction; 4.2 Liver Targeting; 4.2.1 The Beginning; 4.2.2 Broadening the Liver-targeting Pipeline
Text of Note
4.3 Innovations in Liver Targeting4.4 Beyond the Liver; 4.5 Conclusions; References; Chapter 5 Oligonucleotide-based Toll-like Receptor Antagonists and Therapeutic Applications 80; 5.1 Introduction; 5.2 Oligonucleotide-based TLR Antagonists; 5.2.1 Structure-Activity Relationship Studies; 5.2.2 TLR Antagonists; 5.2.3 Inhibitory Activity of TLR Antagonists; 5.2.4 Inhibitory Activity of Clinical Candidates; 5.3 Studies of TLR Antagonists in Disease Models; 5.3.1 Psoriasis; 5.3.2 Systemic Lupus Erythematosus (SLE); 5.3.3 Rheumatoid Arthritis (RA); 5.3.4 Duchenne Muscular Dystrophy (DMD)
0
8
8
8
SUMMARY OR ABSTRACT
Text of Note
Advances in Nucleic Acid Therapeutics provides a broad overview of techniques of contemporary interest in drug discovery.
ACQUISITION INFORMATION NOTE
Source for Acquisition/Subscription Address
Ingram Content Group
Stock Number
3-178-9781788017329
OTHER EDITION IN ANOTHER MEDIUM
Title
ADVANCES IN NUCLEIC ACID THERAPEUTICS.
International Standard Book Number
1788012097
TOPICAL NAME USED AS SUBJECT
Nucleic acids-- Therapeutic use.
MEDICAL-- Pharmacology.
Nucleic acids-- Therapeutic use.
(SUBJECT CATEGORY (Provisional
MED-- 071000
DEWEY DECIMAL CLASSIFICATION
Number
615
.
31
Edition
23
LIBRARY OF CONGRESS CLASSIFICATION
Class number
QP551
Book number
.
A3257
2019
PERSONAL NAME - ALTERNATIVE RESPONSIBILITY
Agrawal, Sudhir
Gait, M. J., (Michael J.)
CORPORATE BODY NAME - ALTERNATIVE RESPONSIBILITY
Royal Society of Chemistry (Great Britain),issuing body.
ORIGINATING SOURCE
Date of Transaction
20200823055829.0
Cataloguing Rules (Descriptive Conventions))
pn
ELECTRONIC LOCATION AND ACCESS
Electronic name
مطالعه متن کتاب [Book]
Y
